Ozempic's Active Ingredient Extended Lifespan in Old Mice. Here's Why
Semaglutide, the active ingredient in Ozempic and Wegovy, extended lifespan in old female mice in a new Nature study from UC Berkeley. Treatment began at 20 months of age and mimicked many benefits of calorie restriction. In a direct comparison, the drug also showed more favourable trajectories than matched calorie restriction in exploratory drive, spatial memory and glucose control. But this is mouse research in females only, with no dosing guidance for humans. Here is what the findings suggest, and what they do not.
High-Dose Semaglutide and Thigh Muscle: What the MRI Shows
A new MRI sub-analysis of the STEP UP trial examined what 72 weeks of high-dose semaglutide (7.2 mg) does to body composition, including the thigh muscles. Fat loss was large, about 11 liters versus placebo, and fat infiltration within thigh muscle fell significantly. Thigh muscle volume dropped by about 1.1 L, a change that missed statistical significance (p = 0.07) but whose confidence interval leans toward loss. With only 55 scanned participants, just six on placebo, and Novo Nordisk involvement, the findings are suggestive rather than conclusive. Here's what the data show, what they can't, and how to protect your muscle on a GLP-1.
Semaglutide Didn't Shrink Human Muscle Cells. So Why the Muscle Loss?
Does semaglutide really eat your muscle? A new GeroScience study put the drug straight onto primary human muscle cells from older adults with obesity, and the cells didn't waste. No atrophy genes switched on, no secretome alarms, and GIP even thickened myotubes after eight days. Semaglutide did modestly dial down glycolytic ATP production, and GLP-1 receptors were barely detectable. The findings point toward indirect causes of lean mass loss, like calorie deficit and reduced loading, though a dish is not a body.
Do Ozempic and Mounjaro Cause Depression? What 20 Studies Found
Do Ozempic and Mounjaro cause depression or suicidal thoughts? A new systematic review of 20 studies plus EMA and FDA assessments says the best evidence doesn't show it. Randomized data, including two large 2025 meta-analyses, found no increased suicidality, depression, or anxiety with semaglutide or tirzepatide. The scarier signals came from study designs that can't separate drug effects from obesity-related distress, baseline psychiatric risk, and reporting bias. But trials excluded many psychiatric patients, so surveillance still matters for high-risk groups and rare long-term outcomes.